This review mainly introduces the concepts of homologous recombination and synthetic lethality, analyzes how PARP inhibitors make use of this mechanism, as well as a general analysis of drug resistance, enumerates several tumor markers that predict the prognosis and therapeutic effect of ovarian cancer, summarizes the application status and achievements of PARP inhibitors in patients with ovarian cancer, lists the potential problems and prospects of PARP inhibitors(PRAPis). This evidence concerns the gene PARP1 and ovarian cancer.